Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival
Concurrent Trastuzumab and Anthracyclines Not Necessary for High Pathological Response
FDA Grants Accelerated Approval to Imbruvica
Two Papers Evaluate CyberKnife Survival Rates and Tolerability
ANG1005 Demonstrates Activity In Patients with Brain Metastases
MM-121 Study Fails PFS Endpoint, Biomarker Analysis Continues
AGS-003 Immunotherapy Induces T Cell Responses in Phase II Trial
NCI CTEP Approved Trials For the Month of November
Trending Stories
- Banished from the institute he founded, separated from his lab materials, Tom Curran sues Children’s Mercy
Whistleblower lawsuit alleges wrongful firing - Tom Sellers steps down as director of OHSU Knight, replaced by Lisa Coussens
Shivaani Kummar recently named interim CEO - DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care - David Liu awarded 2025 Breakthrough Prize in Life Sciences
- Thomas B. Tomasi Jr., Roswell Park president and CEO from 1986 to 1996, dies at 97
An architect of today’s Roswell Park
